That said, further study will be necessary to definitively determine the role of epigenetic inactivation of TCF2 in the molecular mechanism of tumorigenesis and progression of ovarian cancer and its utility as a therapeutic target. This evidence concerns the gene HNF1B and ovarian carcinoma.